Iomx
2 known investors
iOmx is a clinical-stage biotech company developing targeted cancer immunotherapies for common solid tumor indications, translating tumor immune evasion biology into biomarker-enabled drug programs. Its lead program, OMX-0407, is an orally available spectrum-selective inhibitor of salt-inducible kinase (SIK) identified via its iOTarg screening platform.
Investors · 2
Frequently asked questions
- What does Iomx do?
- iOmx is a clinical-stage biotech company developing targeted cancer immunotherapies for common solid tumor indications, translating tumor immune evasion biology into biomarker-enabled drug programs. Its lead program, OMX-0407, is an orally available spectrum-selective inhibitor of salt-inducible kinase (SIK) identified via its iOTarg screening platform.
- Who are Iomx's investors?
- Iomx's investors include M Ventures, Sofinnova Partners.